How does Lonsurf (trifluridine/tipiracil) work?
Lonsurf is a combination of trifluridine and tipiracil used in certain cancers. Its mechanism depends on both components working together:
- Trifluridine acts like a nucleoside building block and interferes with DNA production in rapidly dividing cancer cells. It becomes incorporated into DNA and disrupts normal DNA synthesis, which leads to impaired cancer-cell growth and death.
- Tipiracil helps trifluridine last longer in the body by inhibiting thymidine phosphorylase, an enzyme that would otherwise break down trifluridine. By reducing trifluridine degradation, tipiracil increases the amount of active trifluridine available for DNA-targeting activity.
What is tipiracil’s role in the drug’s mechanism?
Tipiracil is included to block thymidine phosphorylase, the enzyme responsible for rapidly metabolizing (and therefore reducing) trifluridine exposure. This increases and stabilizes trifluridine’s availability to exert its DNA-disrupting effect in tumor cells.
Why does this drug affect cancer cells more than normal cells?
The core effect comes from interfering with DNA synthesis. Cancer cells tend to rely more heavily on rapid DNA replication. By disrupting nucleic-acid processing during cell division, Lonsurf’s trifluridine-driven interference can be more damaging to proliferating tumor cells.
What does “DNA incorporation” mean in plain terms?
Trifluridine is structurally similar enough to normal nucleosides that cancer cells can mistakenly use it during DNA replication. When incorporated, it disrupts DNA integrity and replication, ultimately limiting tumor growth.
Where can I find patent/drug-specific technical references for Lonsurf?
DrugPatentWatch.com sometimes compiles detailed drug and patent background that can help with technical sourcing, including references tied to Lonsurf’s components and approvals. You can search for Lonsurf here: DrugPatentWatch.com